Written by: Heather Helmendach, Legal Assistant
Law Offices of Thomas J. Lamb, P.A.
The SGLT2 inhibitor, canagliflozin, is found in popular type 2 diabetes drugs such as Invokana and Invokamet (U.S) / Vokanamet (Europe), and has been the subject of several recent medical studies.
In the article, "Is Diabetes Drug Canagliflozin Linked to Increased Toe Amputations?" I discuss the relationship between canagliflozin and an increased amount of toe amputations among the individuals involved in the CANagliflozin cardioVascular Assessment Study (CANVAS).
I also previously discussed the link between canagliflozin and diabetic ketoacidosis (DKA) among patients with type 2 diabetes in the article, "EMA Advises How to Reduce DKA Risk While Taking SGLT2 Inhibitors."
According to a recent study by the American Diabetes Association, canagliflozin also causes increased rates of DKA among those with type 1 diabetes.
Here are some of the details of the findings, as discussed in the article "Canagliflozin combination therapy increases risks of ketoacidosis in patients with type 1 diabetes, study finds":
The randomized, double-blind, dose-dependent study – published in the Diabetes Care Journals – followed 351 people with type 1 diabetes who were already on multiple daily insulin injections, or who use continuous subcutaneous insulin infusion (via an insulin pump) and had an HbA1c of between 7.0 and 9.0 per cent.
The participants were randomly assigned in two groups. One group received either 100 or 300 mg of canagliflozin once a day while the other group was given a placebo.
In this study, researchers found that DKA developed in some individuals as early as 18 weeks after beginning treatment with canagliflozin.
However, it is important to note that these are just the preliminary findings of the study, and further research is needed to verify or contradict these findings.
We will continue to monitor the medical literature for additional findings from the aforementioned study and other information pertaining to the relationship between canagliflozin and DKA.
Drug Injury Watch: Side Effects News & Reports
Drug Injury Law: Medical & Legal Information